ASPEN PHARMACARE HOLDINGS LIMITED - Divestment of a portfolio of six South African products to Acino

Divestment of a portfolio of six South African products to Acino

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

DIVESTMENT OF A PORTFOLIO OF SIX SOUTH AFRICAN PRODUCTS TO ACINO

Aspen is pleased to announce that it has concluded an agreement with Acino Pharma AG ("Acino") (a
company incorporated in Switzerland), in terms of which Acino will acquire a product portfolio of six
products for a consideration of approximately R1.8 billion, plus the cost of the related inventory (“the
Transaction”). The products included in the Transaction are sold under the brand names, Altosec, Aspen
Granisetron, Ciavor, Grantryl, Trustan and Zuvamor in South Africa and recorded revenue of R512 million in
the financial year ended 30 June 2021.

The Transaction will be conditional upon the fulfilment of customary conditions precedent applicable to
transactions of this nature. It is anticipated that the Transaction will complete by 31 December 2021.

Aspen and Acino will enter into a Manufacturing and Supply Agreement in terms of which Aspen will supply
the Aspen manufactured products to Acino for 7 years.

The Transaction forms part of Aspen’s communicated strategy to refine its product portfolio in South
Africa.

The proceeds from the Transaction will be used to reduce the Group’s debt.

Durban
22 October 2021

Sponsor
Investec Bank Limited

Date: 22-10-2021 08:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.